Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Date:2/10/2011

ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2010.

"2010 has been an exceptional milestone year in the history of our company.  Our first product, Fanapt®, reached the U.S. market for the treatment of schizophrenia, we had our first profitable year and we have advanced our second asset, tasimelteon, in Phase 3 studies," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer. "2011 will be a foundation year for Vanda, as we begin to execute upon our vision of building a world class neuroscience pharmaceutical company."

Key Highlights:

  • Vanda recorded 2010 revenue of $35.2 million including royalties and product sales of $8.4 million.  
  • Cash and cash equivalents plus marketable securities at year end 2010 were $198.0 million as compared to $205.3 million at year end 2009.
  • Monthly prescriptions of Fanapt®, as reported by IMS, increased from over 6,000 in September of 2010 to over 8,000 in December of 2010. For the full year 2010, more than 55,000 prescriptions have been written.
  • Tasimelteon efficacy and safety studies are ongoing in both the U.S. and Europe.
  • On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal Revenue Service (IRS) clarifying the company's ability to utilize net operating loss carryforwards for tax purposes.  

  • Full Year 2010 Reported ResultsTotal revenues for the full year 2010 were $35.2 million, compared to $4.5 million for the same period in 2009.  2010 revenues included $26.8 million recognized from the $2
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
    4. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
    6. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
    7. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
    9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
    10. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
    11. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... ... September 01, 2015 , ... Leading ... neuro and pain management space join prominent academics and key investors for Neuro ... Harvard Medical School in Boston. , Neuro Advance Boston focuses on the ...
    (Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
    (Date:8/31/2015)... ... 2015 , ... The Global Supply Chain Resiliency Council was ... practitioners with luminaries and thought leaders to advance the professional discipline through opportunities ... and performance excellence. At that time its principle sponsor, Resilinc , stated ...
    (Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Argentina Biomedical Sensors Market - Growth, Trends ... The Argentina Biomedical Sensors market is estimated ... 1.17% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
    Breaking Biology Technology:Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2
    ... , - German Chemical Parks ... The number of employees in German chemical parks ... In this same period, the number of,companies doing business at ... today by Dr. Klaus-Dieter Juszak, Chairman of the,German Sector Group ...
    ... EXPANSION INTO EUROPE AND STRENGTHENS ITS SENIOR MANAGEMENT ... 12 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), ... for clinical trials, today announced that it has strengthened ... of Dr. Wolfgang Summa. As Executive Vice President, Europe ...
    ... today that it has acquired from biotechnology company Antisoma ... film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) ... United States for use as a second-line therapy to ... pleased to add Oforta to our existing oncology portfolio, ...
    Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3
    (Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
    (Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
    (Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
    Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
    ... Vitamin and mineral supplements can enhance mental energy and ... prone to anxiety and depression, according to a July ... Technologists (IFT) Annual Meeting & Food Expo held at ... faculty of medicine at the University of Calgary, Alberta, ...
    ... size and parental behavior are the key drivers in children,s ... the 2013 Institute of Food Technologists (IFT) Annual Meeting & ... crowd of more than 200 conference attendees heard new insights ... eating behaviors are and how the industry and parents can ...
    ... (OGL), New England Biolabs, Inc., and Northeastern University have reached ... tissue from the world,s most rare, strange, and remarkable ocean ... Ocean Genome Legacy , Founded in 2001 ... New England Biolabs, OGL is a non-profit environmental research organization ...
    Cached Biology News:Taste rules for kids and healthy food choices 2Collection that may hold key to ocean's mysteries looks to expand in new waterfront home 2
    ... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
    Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
    ... on one plate. The new ArraySlide 96 ... (7mm x 7mm) individual printing surfaces for ... analysis studies. Unlike other systems, this device ... presence of contaminating adhesives. The chamber itself ...
    ... chambers for sealing hybridization reactions on slides. The ... on a glass slide. Reaction solution is added ... are then sealed with plastic sealing dots. Dots ... of reaction fluid. These chambers enclose a 20 ...
    Biology Products: